Roche’s affiliate Foundation Medicine agreed to acquire SAGA Diagnostics in a transaction valued at up to $595 million, designed to broaden Foundation’s MRD diagnostics portfolio. The deal adds SAGA’s Pathlight platform—using whole-genome sequencing plus digital PCR—to track structural variants with ultra-sensitive precision, and supports plans for decentralized MRD development leveraging Roche sequencing and PCR platforms.